Here are the Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Side effect of semaglutide for weight loss, effect of semaglutide 2 4 mg on pouches, side effect of semaglutide, is hair loss a side effect of semaglutide, is fatigue a side effect of semaglutide, effect of semaglutide 2 4 mg on use of antihypertensive in palliative care, side effects of losartan, side effects of metformin, effect of semaglutide 2 4 mg on use of antihypertensive and lithium, side effects of statins.
Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials
Objective: The objective of this study was to assess antihypertensive and lipid-lowering treatment changes in participants receiving semaglutide 2.4 mg versus placebo across pooled populations from five Semaglutide Treatment Effect in People with Obesity (STEP) trials.
Methods: Efficacy and safety of semaglutide 2.4 mg were evaluated in the STEP clinical trials. In this post hoc analysis, STEP 1, 3, 6, and 8 (which included people with overweight or obesity) and, separately, STEP 2 and 6 (which included people with overweight or obesity and type 2 diabetes) were pooled for analysis. Changes in antihypertensive or lipid-lowering treatment intensity from randomization to end of treatment were evaluated.
Results: In both pooled samples, a higher proportion of participants in the semaglutide 2.4 mg group versus placebo underwent antihypertensive or lipid-lowering treatment intensity reduction by end of treatment. A smaller proportio n underwent antihypertensive or lipid-lowering treatment intensification by end of treatment in the semaglutide 2.4 mg group of both samples versus placebo. In participants receiving antihypertensive or lipid-lowering medications in both samples, greater numeric reductions in body weight were observed in the semaglutide 2.4 mg group versus placebo. Conclusions: These results support a relationship between semaglutide 2.4 mg treatment of overweight and obesity and reduced need for antihypertensive and lipid-lowering treatment, facilitating treatment intensity reduction/discontinuation and abating treatment intensification. (Figure presented.). © 2025 The Author(s). Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.
Authors : Tchang B.G.; Knight M.G.; Adelborg K.; Clements J.N.; Iversen A.T.; Traina A.
Source : John Wiley and Sons Inc
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.1002/oby.24202 |
| ISSN | 19307381 |
| Volume |
You can download the article here
If You have any problem, contact us here